MARKET

GERN

GERN

Geron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.050
-0.020
-1.87%
Pre Market: 0.9900 -0.06 -5.71% 07:32 04/03 EDT
OPEN
1.060
PREV CLOSE
1.070
HIGH
1.080
LOW
1.020
VOLUME
1.83M
TURNOVER
--
52 WEEK HIGH
2.140
52 WEEK LOW
0.7500
MARKET CAP
210.36M
P/E (TTM)
-2.9412
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GERN stock price target is 3.300 with a high estimate of 4.000 and a low estimate of 3.000.

EPS

GERN News

More
  • Geron Provides COVID-19 Related Business Update
  • GlobeNewswire · 22h ago
  • More COVID-19 actions - healthcare
  • Seeking Alpha - Article · 23h ago
  • Geron Expects 2020 Spending To Be Lower Than The $70M-$75M Guidance Range
  • Benzinga · 23h ago
  • Penny Stocks to Buy Using Technical Analysis for April 2020
  • Investopedia · 2d ago

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About GERN

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.
More

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.